Molecule and BIO.xyz are building the foundation of Decentralized Science (DeSci) — where biotech meets web3 to make scientific research community-owned, transparent, and faster to market.
Molecule provides the infrastructure to turn intellectual property (IP) into programmable, on-chain assets through our IP-NFT framework and evolving protocol stack. This enables researchers, patients, and communities to fund and govern biotech projects in new, open ways.
BIO.xyz is the coordination and economic layer of DeSci, powering BioDAOs through funding, governance, and ecosystem alignment.
Together, we are creating a new model for scientific discovery — one where breakthroughs are owned and advanced by the communities that believe in them.
The Role
You will be an AI Scientist at Molecule. In your first four weeks, you will live on-site, embedded with the founding team, and ship your first autonomous agent fleet into production against a real disease area. From day one you own the loop: design the agents, deploy them, pilot them, iterate, and generate scientific output that moves IP forward.
This is not a research role with a roadmap handed to you. You will pick targets, stand up infrastructure, recruit your sub-agents, and prove that autonomous science works at the bench-to-IP level. After the residency, you scale: more fleets, more disease areas, more shots on goal.
What You'll Do
Architect and deploy fleets of scientific agents spanning literature mining, target identification, molecular design, assay design, and data analysis
Pilot each fleet against a specific disease area and drive it to a tangible deliverable — a validated target, a candidate molecule, a novel dataset, an IP-NFT
Run multiple fleets in parallel across disease areas, reporting results directly to the CEO
Own the full stack: agent design, orchestration, evaluation, and scientific judgment on outputs
Define and set the standard for how autonomous science gets done at Molecule
Who You Are
Entrepreneurial to the core. You ship. You don't wait for permission.
Technically deep across LLMs, agent frameworks, and at least one wet-science domain - chemistry, biology, pharma, structural biology, or genomics
Comfortable with ambiguity. You may be the only person in the room who knows how to do what you do, and that energizes you
Credential-agnostic. PhD, MSc, BSc, or straight from high school - output matters, not titles. If you hold a degree, it should be from a top-tier institution (Oxbridge, Ivy League, MIT, Caltech, Stanford, ETH/EPFL, Imperial, or equivalent). If you skipped the degree, show us what you built instead.
All-in on intensity. Willing to live on-site for 4 weeks and operate at founder pace
What We Offer
An early seat at the company building the infrastructure for autonomous science
Direct ownership over a frontier no one else is running at
Equity in the form of $BIO token allocation
The fastest path from idea to deployed IP that exists in biotech today
We are an equal opportunity employer. We are committed to equality and weaving a community that values diverse perspectives and experiences and are actively seeking a diverse pool of applicants. All employment decisions are made without regard to race, colour, national origin, ancestry, sex, gender, gender identity or expression, sexual orientation, age, genetic information, religion, disability, medical condition, pregnancy, marital status, family status, veteran status, or any other characteristic protected by law.
Molecule is building the foundational infrastructure for Decentralized Science (DeSci), where biotech meets web3 to make scientific research community-owned, transparent, and faster to market. The company provides an IP-NFT framework and protocol stack that turns intellectual property into programmable, on-chain assets, enabling researchers, patients, and communities to fund and govern biotech projects in new ways. Together with BIO.xyz—its coordination and economic layer powering BioDAOs—Molecule is creating a new model for scientific discovery where breakthroughs are owned and advanced by the communities that believe in them. The platform spans partnerships across pharma, biotech, academic institutions, and investors, managing concurrent deal workstreams and investor relations across 70+ existing investors.
